NCT03205995: A trial that was reported late by Omeros Corporation
This trial has reported, although it was 855 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03205995 |
|---|---|
| Title | A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Adolescents |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 2, 2018 |
| Completion date | Feb. 2, 2021 |
| Required reporting date | Feb. 2, 2022, midnight |
| Actual reporting date | June 6, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 855 |